Form 4: RA Capital Management Reports Acquisition of Stock Options in Vor Biopharma Inc.

RA Capital Management and related entities report the acquisition of stock options in Vor Biopharma Inc. on behalf of Joshua Resnick, a director, under a non-employee director compensation policy.

Summary

• RA Capital Management, L.P., along with related entities including RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., Peter Kolchinsky, and Rajeev Shah, filed a Form 4 regarding transactions in Vor Biopharma Inc. (VOR).
• The filing reports the acquisition of 30,000 stock options by Joshua Resnick, a director of Vor Biopharma, on May 23, 2024, at an exercise price of $1.61.
• These options were granted under the issuer's non-employee director compensation policy and vest on the earlier of May 23, 2025, or the next annual meeting of stockholders, contingent upon Mr. Resnick's continued service.
• Mr. Resnick holds the options for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund, and any proceeds from exercising the options will offset advisory fees owed by these funds to RA Capital Management.
• RA Capital Management, as the investment manager for the funds, along with its general partner and managing members (Kolchinsky and Shah), disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, suggesting a neutral to slightly positive sentiment due to continued alignment of interests.

Positives

• The acquisition of stock options indicates continued alignment of interests between RA Capital Management and Vor Biopharma.
• The vesting schedule incentivizes continued service by Mr. Resnick as a director.

Future Outlook

The document does not contain specific forward-looking statements regarding Vor Biopharma's future performance.

Management Comments

• RA Capital Management, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
• Mr. Resnick is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser.

Industry Context

This filing is typical for investment firms with board representation in publicly traded companies, ensuring transparency regarding potential conflicts of interest and compensation arrangements.

Comparison to Industry Standards

• Director compensation packages often include stock options to align director interests with shareholder value, a common practice among biotech companies like Vor Biopharma.
• The vesting schedule and exercise price are within typical ranges for director stock option grants, similar to those seen at companies like CRISPR Therapeutics or Beam Therapeutics.

Related Party Transactions

• Mr. Resnick's arrangement with the Adviser, where he holds the option for the benefit of the Fund and the Nexus Fund, and any proceeds will offset advisory fees, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning director interests with company performance.
• The arrangement impacts RA Capital Healthcare Fund and RA Capital Nexus Fund by potentially reducing advisory fees.

Key Dates